0000000000901925

AUTHOR

Andrea Gramegna

showing 5 related works from this author

COVID-19 Vaccine: A Survey of Hesitancy in Patients with Celiac Disease

2021

(1) Background: COVID-19 vaccination campaigns offer the best hope of controlling the pandemic. However, the fast production of COVID-19 vaccines has caused concern among the general public regarding their safety and efficacy. In particular, patients with chronic illnesses, such as celiac disease (CD), may be more fearful. Information on vaccine hesitancy plays a pivotal role in the development of an efficient vaccination campaign. In our study, we aimed to evaluate COVID-19 vaccine hesitancy among Italian CD patients. (2) Methods: an anonymous questionnaire was sent to CD patients followed at our tertiary referral center for CD in Milan, Italy. Patients were defined as willing, hesitant an…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)ImmunologyCOVID-19 vaccinesDiseaseArticle03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryPandemicMedicinePharmacology (medical)Adverse effectPharmacologyResponse rate (survey)business.industryRCOVID-19Odds ratiovaccinesConfidence intervalVaccinationInfectious Diseases030220 oncology & carcinogenesisMedicinevaccine hesitancy030211 gastroenterology & hepatologybusinessCOVID-19 vaccineceliac diseaseVaccines
researchProduct

Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study

2022

High-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE). Methods: This is a retrospective bicentric case-control study of outpatients with BE on optimized medical treatment with a severe exacerbation requiring hospitalization in the previous year. Patients on long-term home HFNT (cases) and patients on optimized medical treatment alone (controls) were matched by age, sex, bronchiectasis severity index, and exacerbations in the previous year. Data on BE exacerbations, hospitalizations/year, mucus features, respiratory symptoms, and pulmonary func…

bronchiectasis; exacerbation; high-flow nasal cannula; high-flow nasal therapy; hospitalization; mucus;exacerbationbronchiectasis; exacerbation; high-flow nasal cannula; high-flow nasal therapy; hospitalization; mucushigh-flow nasal cannulahigh-flow nasal cannula; high-flow nasal therapy; bronchiectasis; mucus; exacerbation; hospitalizationbronchiectasismucusSettore MED/10 - Malattie dell'Apparato Respiratoriohigh-flow nasal therapyGeneral Medicinehospitalization
researchProduct

Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE)

2018

Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients …

medicine.medical_specialtyBronchiectasisSputum colourCopd patientsbusiness.industrySputum Productionmedicine.diseaseDisease severityInternal medicineSecondary analysisCohortmedicineSputummedicine.symptombusiness
researchProduct

Additional file 1: of Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective

2018

Table A: Tables with testing frequencies for specific atypical pathogens across continents (A1: Testing frequencies for C. pneumoniae across continents; A2: Testing frequencies for M. pneumoniae across continents; A3: Testing frequencies for L. pneumophila across continents).- Brief description of the data: a table in three parts reporting data about frequency of testing for different atypical pathogens across different continents. (DOC 50â kb)

researchProduct

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

2018

Abstract Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromis…

0301 basic medicineMalePediatricsEtiologyMultidrug-resistant pathogenMRSAPneumocystis pneumoniaPneumònia adquirida a la comunitatHOSPITALIZED-PATIENTS0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsPrevalenceMedicine030212 general & internal medicinePNEUMOCYSTIS PNEUMONIAArticles and CommentariesAged 80 and overRespiratory tract infectionsAnemia AplasticMiddle Aged3. Good healthCommunity-Acquired InfectionsEuropeInfectious DiseasesImmunocompromise; Microbiology; MRSA; Multidrug-resistant pathogens; PneumoniaEtiologiaHematologic NeoplasmsFemaleBLOOD-STREAM INFECTIONSLung TransplantationMicrobiology (medical)medicine.medical_specialtyAsiaNeutropeniaCommunity-acquired pneumonia030106 microbiologyRESPIRATORY-TRACT INFECTIONSHematologic NeoplasmsSettore MED/10 - Malattie Dell'Apparato RespiratorioTRANSPLANT RECIPIENTSDISEASES-SOCIETYMicrobiology03 medical and health sciencesImmunocompromised HostPneumonia BacterialMANAGEMENTHumanspneumoniaBACTERIAL PNEUMONIAImmunocompromiseAgedAcquired Immunodeficiency Syndromebusiness.industrymicrobiologyBacterial pneumoniaAustraliaPneumoniamedicine.diseaseMultidrug-resistant pathogensPneumoniamultidrug-resistant pathogensMycosesBacteremiaAfricaEtiologyRISK-FACTORSimmunocompromiseAmericasbusinessClinical Infectious Diseases
researchProduct